Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00476047 · ClinicalTrials.gov registry record · Phase 2
Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00476047 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 16 participants.
The verdict
NCT00476047, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This phase II trial studies how well tositumomab and iodine I 131 tositumomab works in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that have had their first decrease in or disappearance of signs and symptoms of cancer (first remission). Monoclonal antibodies, such as tositumomab and iodine I 131 tositumomab, may block cancer growth in different ways by targeting certain cells.
Interventions
- COMBINATION_PRODUCT Tositumomab and Iodine I 131 Tositumomab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-02 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00476047
The ClinicalTrials.gov registry entry for NCT00476047 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tositumomab and Iodine I 131 Tositumomab is the first listed.
NCT00476047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00476047 about?
NCT00476047 is a clinical study titled "Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission". This phase II trial studies how well tositumomab and iodine I 131 tositumomab works in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that have had their first decrease in or disappearance of signs and symptoms of cancer (first remission). Monoclonal an...
What is the current status of trial NCT00476047?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2007-02. Estimated completion is 2015-02.
What interventions are being tested in trial NCT00476047?
The interventions under investigation include: Tositumomab and Iodine I 131 Tositumomab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT00476047?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.